

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 25, 2007

Access Pharmaceuticals, Inc.

-----  
(Exact name of registrant as specified in its charter)

Delaware                  0-9314                  83-0221517

-----  
(State of Incorporation) (Commission File Number) (I.R.S. Employer  
Identification No.)

2600 Stemmons Freeway, Suite 176, Dallas, Texas                  75207

-----  
(Address of principal executive offices)                  (Zip Code)

Registrant's telephone number, including area code: (214) 905-5100

-----

Item 1.01 Entry into a Material Definitive Agreement

-----

On July 25, 2007, Access Pharmaceuticals, Inc. ("Access") entered into an amendment to its 7.0% (Subject to Adjustment) Convertible Promissory Notes with Oracle Partners LP, Oracle Institutional Partners LP, SAM Oracle Investments Inc. and Oracle Offshore Ltd. agreeing to extend the maturity date of the notes to September 7, 2007 from July 27, 2007. The principal amount of the notes in the aggregate total \$4,015,000.

On July 25, 2007, Access entered into an amendment to its 7.5% Convertible Notes with SCO Capital Partners LLC, Beach Capital LLC and Lake End Capital LLC agreeing to extend the maturity date of the notes to September 6, 2007 from July 26, 2007. The principal amount of the notes in the aggregate total \$6,000,000.

All other terms of the notes remain the same.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Access Pharmaceuticals, Inc.  
(Registrant)

By: /s/ Stephen B. Thompson

-----  
Stephen B. Thompson  
Vice President and  
Chief Financial Officer

Dated July 26, 2007